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Background: Amyloid-β peptide ending at 42nd residue (Aβ42) is believed as a pathogenic peptide for Alzheimer
disease. Although γ-secretase is a responsible protease to generate Aβ through a processive cleavage, the proteo-
lytic mechanism of γ-secretase at molecular level is poorly understood.
Results: We found that the transmembrane domain (TMD) 1 of presenilin (PS) 1, a catalytic subunit for the γ-
secretase, as a key modulatory domain for Aβ42 production. Aβ42-lowering and -raising γ-secretase modulators
(GSMs) directly targeted TMD1 of PS1 and affected its structure. A point mutation in TMD1 caused an aberrant se-
cretion of longer Aβ species including Aβ45 that are the precursor of Aβ42. We further found that the helical sur-
face of TMD1 is involved in the binding of Aβ45/48 and that the binding was altered by GSMs as well as TMD1
mutation.
Conclusions: Binding between PS1 TMD1 and longer Aβ is critical for Aβ42 production.
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Several lines of evidence suggest that the accumulation
of amyloid-β peptide (Aβ), a major component of senile
plaques, is a common pathological feature in Alzheimer
disease (AD) [1]. Aβ is generated through sequential
cleavage by β- and γ-secretases of amyloid-β precursor
protein (APP). γ-Secretase primarily cleaves APP to pro-
duce a C-terminal stub of APP (APP-CTF). Then, scis-
sion of APP-CTF by γ-secretase results in generation of
various forms of Aβ with different C-terminal lengths.
Especially, Aβ ending at the 42nd residue (Aβ42), the
most aggregable species, is initially and predominantly
deposited in AD brains [2]. Moreover, familial AD-
linked mutations in Psen (Presenilin; PS) 1, Psen2 or
APP genes cause an increase in Aβ42 generation. Thus,
Aβ42 is considered as the most pathogenic species
causative for AD [3].
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stated.PS, Nicastrin, Aph-1 and Pen-2 [4,5]. Extensive bio-
chemical studies showed that the γ-secretase-mediated
intramembrane cleavage of APP occurs in a processive
manner [6]; APP-CTF is primarily cleaved at the ε-site
located around the membrane-cytoplasm boundary to
produce Aβ49 or Aβ48. Subsequently, these longer Aβ
peptides are processed by stepwise cleavages to secrete
shorter Aβ in two predominant production lines: Aβ49
is processed to Aβ43/40 via Aβ46 (Aβ40 production
line), and Aβ48 is processed to Aβ42/38 via Aβ45 (Aβ42
production line). PS forms a channel-like catalytic pore
structure within the membrane, and is endoproteolyzed
to generate N- and C-terminal fragments (NTF and
CTF, respectively) during the assembly of the protease-
active complex [7,8].
Recently, small compounds that selectively regulate
Aβ42 production without affecting ε-cleavage emerged,
which are termed γ-secretase modulators (GSMs) [9].
We have shown that a potent Aβ42-lowering compound,
GSM-1, directly targets the PS1 TMD1 [10]. Moreover,
using substituted cysteine accessibility method (SCAM),
we identified two different regions within TMD1 of PS1,
i.e., a hydrophobic luminal region and a hydrophilic por-
tion facing the catalytic site [11], that are differentlyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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cise molecular mechanism whereby γ-secretase gener-
ates Aβ42, as well as the role of TMD1 in Aβ42
production, remains elusive. In this study, we identified
TMD1 of PS1 as a regulatory domain for the processive
cleavage of the Aβ42 production line.
Results
Fenofibrate directly targets the N-terminal fragment of
presenilin 1
Fen-B [12] is a derivative of the Aβ42-raising GSM,
fenofibrate [13], coupled to a biotin moiety. Previous re-
port showed that Fen-B directly targeted APP-CTF by
photo-crosslinking using recombinant proteins or mi-
crosomes under overexpression conditions. However, the
possibility of a nonspecific binding of fenofibrate to high
concentrations of APP in an artificial condition was not
excluded [14,15]. We performed a photoaffinity labeling
experiment with Fen-B using microsomes prepared from
brains of wild-type mice. We found that endogenous
PS1 NTF, but neither of other γ-secretase components
(i.e., PS1 CTF, Nicastrin, Aph-1 and Pen-2) nor APP-
CTF, was specifically precipitated (Figure 1A). In
addition, we detected a biotinylated band of ~30 kDa,Figure 1 Fen-B directly targets PS1 and SPP. (A) PAL experiments using
peted by treatment with fenofibrate (200 μM). Note that only PS1 NTF was
band with ~30 kDa corresponding to PS1 NTF (an asterisk). (B) Fen-B labeli
His-tagged PS1 was purified with Ni2+-affinity column and analyzed by imm
dimeric SPP (arrows) in CHO cell membranes.corresponding to the molecular weight of PS1 NTF, in
the fraction incubated with Fen-B. To further confirm
the specificity of labeling of PS1 NTF by Fen-B, mem-
brane fractions of fibroblasts from Psen1-/-/Psen2-/-
double knockout mice (DKO) [16] with or without over-
expression of His-tagged PS1 [17] were subjected to
PAL. Biotinylated PS1 NTF was specifically precipitated,
indicating that PS1 NTF is targeted by Fen-B (Figure 1B).
Finally, a specific binding of Fen-B to SPP, another
aspartic intramembranous cleaving protease, which
shared homology with PS [18], was also observed (Fig-
ure 1C). Taken together, we concluded that the bona fide
molecular target of fenofibrate, in the context of modu-
lation of intramembrane cleavage, are PS1 and SPP, i.e.,
the enzyme moieties.
To narrow down the fenofibrate binding site within
PS1 NTF, we employed the limited digestion approach
by inserting a thrombin substrate sequence into PS1
[10]. γ-Secretase containing PS1-Th1 mutant, in which
thrombin cleavable sequence was inserted between D110
and G111 in the hydrophilic loop 1, harbored γ-
secretase activity and was sensitive to fenofibrate (Fig-
ure 2A). Eight kDa N-terminal fragment of PS1 NTF
generated by thrombin cleavage of PS1-Th1 after Fen-Bmouse brain membranes by Fen-B (10 μM). This labeling was com-
specifically labeled by Fen-B. Anti-biotin antibody also reacted with a
ng experiment for the DKO cells expressing His-tagged PS1. After PAL,
unoblotting. (C) Fen-B also bound endogenous monomeric as well as
Figure 2 Cytosolic side of TMD1 forms a fenofibrate binding pocket. (A) Sensitivity of PS1-Th1 for GSMs. Effect of DAPT (10 μM), GSM-1
(1 μM), NS-1017 (1 μM) and fenofibrate (50 μM) on secreted Aβ from wild-type PS1 containing γ-secretase using DKO cells stably expressing
APPNL (n = 3, mean ± SD, *p < 0.01, **p < 0.05 at Student’s t test). (B) Thrombin digestion experiments were performed after PAL by GSM-1-BpB
(1 μM), GSM-1-amide-BpB (1 μM) and Fen-B (10 μM). Note that cleaved Th1-fragment (arrowhead) was precipitated and detected by anti-PS1 NTF
antibody. (C) Labeling competition analysis of Fen-B (10 μM) in the presence of fenofibrate (100 μM) using PS1-Th1 microsomes. Upper and lower
panels show short and long exposures, respectively. (D) Labeling competition analyses were performed with fenofibrate (100 μM), L-685,458
(10 μM), GSM-1 (100 μM) and NS-1017 (100 μM) for the labeling of PS1 NTF by Fen-B (10 μM). (E) Labeling competition experiment with L-
685,458 (10 μM) and fenofibrate (100 μM) for the labeling of PS1 NTF by L-852,646 (100 nM). (F) Labeling competition analysis by GSM-1-BpB
(1 μM) in the presence of GSM-1 (100 μM) or fenofibrate (100 μM) using CHO cell microsomes. (G) SCAM analyses of microsomes from DKO cells
expressing single-Cys mt PS1 containing one Cys at 82 or 85 positions in the presence or absence of indicated compounds. Note that the label-
ing of V82C was decreased and of L85C was increased by preincubation with fenofibrate. (H) Alignment of amino acid residues of PS1 TMD1
(78th to 100th residues) and 37th to 58th residues of SPP, which includes predicted TMD1 (32nd to 54th residues [19]). Asterisks and colons indi-
cate conserved and similar amino acids, respectively.
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fashion to that by phenylpiperidine-type photoprobes,
suggesting that Fen-B also targets to the most N-
terminal region of PS1, including TMD1 (Figure 2B andC). We showed that the cytosolic side of TMD1 partici-
pates in the catalytic hydrophilic pore [7,11]. To analyze
the relationship between the fenofibrate binding site and
the catalytic site within TMD1, we employed the cross-
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classes of compounds. Labeling of PS1 NTF by Fen-B
was diminished by L-685,458, that directly targets the
cytosolic side of TMD1 (Figure 2D) [11]. Consistent with
this, labeling of PS1 NTF by L-852,646, an L-685,458-
based photoprobe, was inhibited by fenofibrate (Fig-
ure 2E). In contrast, neither GSM-1 nor NS-1017, which
targets the luminal region of TMD1, affected the binding
of Fen-B (Figure 2D). Moreover, biotinylation of PS1
NTF by GSM-1-BpB was hardly affected by fenofibrate
(Figure 2F), suggesting that the binding site of fenofi-
brate is distinct from that of GSM-1 within TMD1. We
then performed a labeling competition experiment in
SCAM [7,11], the latter being a biochemical method to
deduce the structure of the membrane protein by
position-specific biotinylation and to identify the target-
ing site of the compound of interest. Preincubation of
fenofibrate decreased the biotinylation at Val82, support-
ing the notion that fenofibrate targets the catalytic site.
In contrast, labeling of Leu85 was increased, indicating
that fenofibrate evokes a conformational change of the
catalytic site in TMD1 (Figure 2G). Intriguingly, Gly37
to Ala58 of SPP, which encompassed the predicted SPP
TMD1 (Ile32 to Ser54) [19], showed a substantial hom-
ology to primary sequence of N-terminal region of PS1
TMD1 (i.e., Gly78 to Ile100) (Figure 2H), suggesting theFigure 3 Pro88 is the critical amino acid residue for the determinatio
from DKO cells expressing Single-Cys mt PS1. Conditioned media were ana
Cys-less) at Student’s t test). (B) Immunoblotting analysis of DKO cell lysate
(C) Aβ42(43)/Aβ40 ratio in secreted Aβ from DKO cells in (B) measured by
from DKO cells expressing wild-type PS1, PS1 with P88L or PS1 with L166P
also analyzed. Two types of Urea-SDS gels were used to obtain better resopossibility that fenofibrate targets to the predicted SPP
TMD1. Taken together with the results of chemical bio-
logical experiments, the binding site of fenofibrate was
estimated to locate around Val82 in TMD1, leading to
the conformational change of the catalytic site of γ-
secretase.
Intermediate longer A was secreted by TMD1 mutant PS1
This finding prompted us to hypothesize that TMD1 is
potentially involved in the regulation of the processivity
of γ-secretase to generate Aβ42. To address this issue,
we screened single cysteine (single-Cys) mutants of
TMD1 in cysteine-less PS1 used in SCAM. While
cysteine-less PS1 increased Aβ42(43)/Aβ40 ratio com-
pared to that of wild-type PS1-expressing cells, some
single-Cys mutants showed further augmentation in
Aβ42(43)/Aβ40 ratio (Figure 3A). Among these mutants,
P88C mutant showed a dramatic increase in the Aβ42
(43)/Aβ40 ratio. To further analyze the functional sig-
nificance of Pro88 in the processive cleavage, we ana-
lyzed two PS1 mutants, P88C and P88L. Surprisingly,
P88L mutation caused an increase in the Aβ42(43)/Aβ40
ratio, to a level higher than that with L166P mutant PS1
(Figure 3C and D), one of the most potent pathogenic
PS1 mutations [20]. In addition, P88L mutant elicited se-
cretion of the intermediate, longer form of Aβ, i.e. Aβ45n of length of secreted Aβ. (A) Aβ42(43)/Aβ40 ratio in secreted Aβ
lyzed by ELISA (n = 3, mean ± SD, *p < 0.05, **p < 0.01 (Compared with
expressing PS1 mutant carrying P88C or P88L by indicated antibodies.
ELISA (n = 3, mean ± SD). (D) Urea-SDS gel analysis for secreted Aβ
mutation. Conditioned media of cells treated with 10 μM DAPT were
lution in the detection of longer Aβ peptides (i.e., Aβ45 and Aβ46).
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tant PS1 (Figure 3D). These data strongly implicated
TMD1 in the regulation of the C-terminal length of Aβ.
GSMs and P88L mutation affected the interaction
between TMD1 and longer Aβ species
Our unexpected observation of an abnormal secretion of
longer Aβ45 from cells expressing P88L mutant PS1
prompted us to further investigate the functional role of
TMD1 during the enzymatic process, especially the pro-
cessive cleavage. Notably, previous reports indicated that
a region between Val82 to Ser132 encompassing TMD1
directly participates in the interaction with γ-secretase
substrates (i.e., APP-CTF) in vitro [21-23]. Moreover,
Aβ46 has been shown to accumulate by DAPT, which
inhibits processive cleavage, and to be coimmunopreci-
pitated with PS1 [23,24]. These results implied the possi-
bility that TMD1 directly recognizes the longer Aβ
species during the processive cleavage of γ-secretase. To
test this idea, we performed in vitro binding assays of
various longer Aβ species with purified GST, GST-PS11-
110 and GST-TM1mt1-110, the latter harboring the TMD1
sequence (i.e., Val82 to Ile100) replaced with a TMD of
an unrelated membrane protein, CLAC-P [10,25] (Fig-
ure 4A and B). Replacement of TMD1 of PS1 with
CLAC-P sequence abolished the γ-secretase activity [17]Figure 4 GSMs and P88L mutation alter interaction of TMD1 of PS1 w
in this study. (B) GST and GST-fused recombinant proteins were purified by
recombinant proteins was confirmed by silver staining. (C) GSM-1-BpB (4 n
GST-TM1mt1-110 (0.19 μg). Samples were preincubated with photoprobes o
GST-fused recombinant proteins mixed with longer Aβ (Aβ43/45/46/48/49)
washed and subjected to immunoblot. (E) The effects of GSM-1 (25 μM) or
Aβ peptides. Recombinant proteins were preincubated with GSMs and the
down by glutathione sepharose and analyzed by immunoblot. (F) The effe
(G) Binding of Aβ48 peptide to native PS1 protein expressed in mammalia
shown at the below (n = 3, mean ± SD, ***p <0.001 at Student’s t test).as well as binding of GSM-1-BpB in vitro [10] (Fig-
ure 4C), indicating chimeric PS1 with CLAC sequence
has a distinct property. Then synthetic Aβ peptides were
coincubated with recombinant proteins and pulled down
by glutathione sepharose (Figure 4D). In this condition,
we detected specific binding of recombinant C99-FLAG
to GST-PS11-110, as previously reported by Annaert et al
[21]. In addition, we detected binding of all synthetic
longer Aβ peptides (Aβ49, Aβ48, Aβ46, Aβ45, Aβ43)
with GST-PS11-110, suggesting that TMD1 of PS1 dir-
ectly binds to longer Aβ peptides, and that the cytoplas-
mic domain of APP is not involved in this binding.
Unexpectedly, GST-TM1mt1-110 was capable of interact-
ing with C99-FLAG as well as with peptides belonging
to the Aβ40 production line (Aβ49, Aβ46 and Aβ43).
However, the binding of Aβ species of the Aβ42 produc-
tion line (i.e., Aβ48 and Aβ45) was significantly reduced
by swapping the TMD1 sequence (Figure 4D). We fur-
ther analyzed the effect of TMD1-targeting GSMs as
well as P88L mutation on the binding of Aβ45 and Aβ48
to TMD1. Intriguingly, GSM-1 augmented the inter-
action of TMD1 with Aβ45 as well as Aβ48, whereas it
was reduced by fenofibrate (Figure 4E). In addition,
introduction of P88L mutation in GST PS1-1-110 de-
creased the pull down of Aβ45 (Figure 4F). Finally, we
observed a specific binding of Aβ48 with native PS1ith Aβ45. (A) Schematic representation of recombinant proteins used
glutathione sepharose and/or Mono Q column. The purity of purified
M) labeling experiment for GST-PS11-110 and TMD1 swapping mutant,
n ice for 10 min, and then irradiated for 60 min. (D) Pull down assay of
(1 nM). After incubation with glutathione sepharose, all samples were
fenofibrate (100 μM) on the interaction of GST-PS11-110 with longer
n incubated with longer Aβ peptides. Protein complexes were pulled
ct of P88L mutation on the binding of Aβ45 peptide to GST-PS11-110.
n cells. Densitometric analysis of relative levels of the bound Aβ48 was
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action was almost diminished by the P88L mutation
(Figure 4G). We did not observe specific binding of
Aβ45 with PS1 holoprotein expressed in mammalian
cells, presumably due to weak binding of Aβ45 to PS1
protein. Nevertheless, these data suggest that the proces-
sivity of the γ-secretase for Aβ42 production is defined
by the tenacity of interaction between TMD1 and longer
Aβ, which may determine the retention of the substrate
in the catalytic site. Collectively, we uncovered the sig-
nificant function of TMD1 of PS1 as a binding site for
the longer Aβ species, especially Aβ45 and Aβ48, during
the processive cleavage of the Aβ42 production line, and
the effects of GSMs on Aβ42 production by changing
the affinity between TMD1 and the longer Aβ peptides.
Discussion
Understanding the molecular mechanism of the proces-
sive cleavage by γ-secretase is critical to the develop-
ment of effective GSMs. We previously reported that
phenylpiperidine-type GSMs are bound to TMD1 of PS1
[10]. Here, we further showed that fenofibrate, an Aβ42-
raising GSM, also directly targets TMD1, while Fen-B
was reported as APP-targeting photoprobe [12]. Re-
cently, some papers reported that large amount of Aβ42
or C99 forms aggregates that cause non-specific binding
to GSMs [14,15]. Therefore, we have used brain micro-
somes obtained from wild-type mouse for the photo-
crosslinking experiment.
Scissile bonds for processive cleavage by γ-secretase
have hypothetically been mapped on different surfaces in
the α-helical model of APP TMD [26]. This raises the
possibility that the distinct processive cleavages by γ-
secretase, i.e., those leading to production of Aβ49-46-
43-40 or Aβ48-45-42-38, are determined by the recogni-
tion of one or the other of the specific helical surfaces.
However, the domain on γ-secretase that recognizes the
helical surface on the substrate is yet to be identified. It
has previously been suggested that TMD1 of PS1 is in-
volved in the binding of APP-CTF, a direct substrate of
γ-secretase [21,22]. Here we found that longer Aβ pep-
tides that are generated as intermediate products in the
Aβ42 production line (i.e., Aβ45 and Aβ48), which also
are direct substrates for the processive cleavage, retain
the capacity to interact with TMD1 of PS1. It is highly
likely that the “gripping tenacity” of the substrate bind-
ing site facing the catalytic pore would determine the
processivity of Aβ48 and Aβ45 on the Aβ42 production
line, which can be modulated by small compounds. Con-
sistently, Okochi et al. have recently reported that Aβ42
is bound to the γ-secretase complex [27] and the bind-
ing was modulated by GSMs, although they have not
identified the binding site of Aβ within the enzyme com-
plex. Thus, we propose that TMD1 of PS1 functions as abinding site of longer Aβ species for γ-secretase during
the processive cleavage, which specifically determines
the efficiency of the processive cleavage of the Aβ42
production line. Structural analyses suggested that the
catalytic cavities of rhomboid protease [28], another
intramembrane-cleaving enzyme, or those of FlaK [29]
and PSH [30], archaeal GxGD proteases, are unable to
accommodate all the amino acid residues of the trans-
membrane sequence of the substrates. This suggests that
a major part of the TMD of substrates remains within
the membrane and is gripped by enzymes to incorporate
the cleavage site into the intramembrane catalytic site
during proteolysis. While the precise structure of human
PS1 still remains unclear, our SCAM results on PS1 [11],
as well as the recently reported x-ray crystal structure of
PSH [30], the latter being composed of 9-transmembrane
domains similarly to human PS1, altogether suggested that
TMD1 locates in proximity to the catalytic aspartate in
TMD7. The results of these structural analyses also
support our notion that TMD1 functions as a substrate
binding domain during the processive cleavage by γ-
secretase.
TMD1 of PS1 bound not only to longer Aβ peptides
of the Aβ42 production line, but to those of Aβ40 line
(Figure 4D). P88L mutation in TMD1 of PS1 caused an
increased secretion of not only Aβ45, but also Aβ43 and
Aβ46 (Figure 3F), suggesting that the interaction be-
tween TMD1 and longer Aβ species is also critical for
the processivity in the Aβ40 production line. Intri-
guingly, swapping TMD1 sequence of PS1 with that of
CLAC-P, an unrelated membrane protein, did not affect
the binding of Aβ43, Aβ46 and Aβ49 peptides. In the
helical net diagram, similar side chains at the luminal
side of PS1 TMD1 and CLAC-P TMD comprised an
interface on the α-helical model only in one side (Fig-
ure 5A and B) [31]. Thus, one helical surface of TMD1
is involved in the binding of longer Aβ species in the
Aβ40 production line, whereas the other surface specif-
ically interacts with those in the Aβ42 production line in
the PSH-based PS1 model (Figure 5C). Pharmacological
and chemical biological studies suggest that the sub-
strate enters the catalytic site via the initial substrate
binding site, in which TMD2, 6 and 9 are involved [17].
Especially, TMD6 and 9 have been implicated in the lat-
eral entry of the substrate from the crystal structure of
PSH [30]. However, helical peptide-type GSIs that target
the initial substrate binding site equally inhibited the pro-
duction of Aβ40 or Aβ42 [32,33]. Thus, we hypothesize
that C99 or longer Aβ is gripped by TMD1 after the lat-
eral entry (Figure 5D). Structural model also suggested
that residues related to the Aβ42 production line in the lu-
minal side of TMD1 are located on the surface of PS1
polypeptide, which might be targeted by GSM-1 [10]. In
fact, several side chain interactions have been identified in
Figure 5 Hypothetical model of the role of PS1 TMD1 in Aβ42 generation. (A and B) Alignment of amino acid residues of the human PS1
TMD1 and CLAC-P. In the swap mutant PS1, 82nd to 100th residues were replaced with CLAC-P TMD. Residues with similar side chains are labeled
with asterisks in (A) and as yellow circles in (B). (C) Modified structural model of PS1 based on PSH structure kindly provided from Dr. Y. Shi [30].
Side views of the ribbon model of TMD1, 6 and 7 generated by Pymol are shown. Yellow and purple residues correspond to those in (B). Possible
approaches to the catalytic aspartates (red spheres) for Aβ40 and Aβ42 production lines are shown by yellow and purple arrows, respectively.
TMD1 grips the substrate to prevent its liberation during the processive cleavage. Helix-helix interaction of longer Aβ with TMD1 determines the
major production line (i.e., Aβ40 or Aβ42) of processive cleavage. (D) Top views of the whole PS1 model (left; ribbon diagram; right, surface
model) generated by Pymol are shown. Putative substrate entry site [30] is shown as black arrows.
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have previously suggested a piston-like vertical move-
ment of TMD1 by SCAM [34], supporting our view that
dynamic conformational changes would take place dur-
ing the catalytic reaction. Intriguingly, the reason why
the efficiency of Aβ42 production is always lower than
that of Aβ40 in any cell types [35] has been unknown.
Considering the positions of the first ε-cleavage sites lo-
cated on the opposite sides of the helical surfaces pre-
dicted for the Aβ40 and Aβ42 production lines, it is
tempting to speculate that an approach of the substrate
from an unfavored direction (pink arrow, Figure 5) to
the catalytic site in terms of stereochemistry might ex-
plain the lower efficiency of cleavage in the Aβ42 pro-
duction line (Figure 5C and D). However, the other
TMDs might be also involved in the recognition of
Aβ42, and GSMs could allosterically affect these other
regions including initial substrate binding site in PS1.
Biochemical analysis to identify the other binding
domain for longer Aβ peptides belonging to the Aβ40
production line would provide further molecular in-
sights regarding the mechanism of action of GSMs. Also
structural analysis of mammalian PS1 carrying P88Lmutation might unveil further mechanistic role of
TMD1 in the trimming process by γ-secretase. In sum,
we revealed that TMD1, a previously identified target
region of GSMs, participates in the Aβ42 generation as
a binding site that docks longer Aβ species as inter-
mediate substrates for γ-secretase. Our observations
may shed light on the molecular mechanism of the
processive cleavage by γ-secretase, contributing to the
development of potent and selective Aβ42-lowering
compounds for AD.
Conclusions
Fenofibrate directly bound to TMD1 of PS1 to induce
the conformational changes in the catalytic site of the γ-
secretase. P88L mutation in TMD1 caused an aberrant
secretion of longer Aβ polypeptides (i.e., Aβ45 or Aβ46),
indicating that TMD1 is involved in the regulation of C-
terminal length of Aβ. Finally, we found that TMD1
contains a binding site for the longer Aβ species, and
GSMs affect Aβ42 production by changing the affinity
between TMD1 and longer Aβ. Our results suggest that
TMD1 functions as a substrate binding domain during
the processive cleavage by γ-secretase.
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Compounds, peptides and antibodies
GSM-1, GSM-1-BpB, NS-1017, GSM-1-amide-BpB, Fen-
B and DAPT were synthesized as described [10,12,36].
L-685,458 and fenofibrate were purchased from Bachem
and SIGMA, respectively. L-852,646 [37] was kindly pro-
vided from Dr. Y. Li (Sloan-Kettering Cancer Center).
Synthetic longer Aβ peptides (i.e., β-amyloid (1-43,
#23573), (1-45, #61956-01), (1-46, #62076-01), (1-48,
#61965-01), (1-49, #61963-01) were purchased from
Anaspec. Aβ (1-40) (#4307-v) and Aβ (1-42) (#4349-v)
peptides were purchased from Peptide institute. The
rabbit polyclonal antibodies anti-PS1 NTF (G1Nr5),
anti-PS1 CTF (G1L3) and anti-Pen-2 (PNT3) were
raised as described [38-40]. Anti-PS1 NTF (PS1NT) [41]
and anti-SPP (SPPc) [42] were kindly gifted from
Drs. G. Thinakaran (The University of Chicago) and
T. Golde (University of Florida). Anti-nicastrin N1660
(SIGMA), anti-APP CTF (Immuno-Biological Labora-
tories), anti-Aph-1aL O2C2 (Covance), anti-human Aβ
82E1 (Immuno-Biological Laboratories) and anti-biotin
(Bethyl) were purchased from indicated vendors. The
monoclonal antibody anti-α-tubulin AA4.3 developed
by Dr. C. Walsh was obtained from the Developmental
Studies Hybridoma Bank developed under the auspices
of the NICHD, National Institutes of Health, and main-
tained by The University of Iowa, Department of Biol-
ogy, Iowa City, IA.
Plasmid construction, cell culture manipulation and cell
based assay
cDNAs encoding PS1 and APP carrying Swedish muta-
tion (APPNL) were inserted into pMXs-puro [43].
cDNAs encoding mutant PS1 were generated by long
PCR-based QuikChangeTM strategy (Stratagene). To pro-
duce recombinant proteins, cDNAs encoding PS1 were
cloned into pGEX-6P-1 vector (GE healthcare) [10].
Maintenance of cultured cells, transfection, retroviral in-
fection, two-site enzyme-linked immunosorbent assay
(ELISA), or immunoblotting using Urea/SDS-PAGE gel
system as described [10,39,44,45].
Photoaffinity labeling and SCAM experiments
Preparation of samples for photoaffinity labeling experi-
ments [46] was performed as follows. Brains of C57J/B6
mouse (3-5 month age) or cultured cells were homoge-
nized with homogenize buffer (20 mM HEPES (pH 7.0),
140 mM KCl, 250 mM sucrose, 0.5 mM diisopropyl flu-
orophosphate, 0.5 mM phenylmethylsulfonyl fluoride,
1 μg/ml tosyllysine chloromethyl ketone, 1 μg/ml anti-
pain, 1 μg/ml leupeptin, 10 μg/ml phosphoramidon,
5 mM EDTA, 1 mM EGTA) using Potter-Elvehjem
Tissue Grinder (Wheaton), and membrane fractions
were collected by ultracentrifugation at 100,000 × g(Beckman) [10]. PAL experiments utilizing avidin-biotin
catch principle [47] and thrombin digestion experiments
after PAL were performed as previously described [10].
Briefly, after resuspension of the microsome in the
homogenize buffer by 25G needle with syringe, protein
content was measured by BCA assay (Thermo Fisher
Scientific). 1 mL of microsome-containing solution
(1 mg/ml protein) was preincubated with compounds
for 30 min on ice. Then photoprobes were added and in-
cubated for 10 min on ice under the dark condition. UV
irradiation (352 nm) was performed on ice for 1 hr with
a UV lamp (Model XX-15BLB, UVP). The approximate
distance from UV lamp to the samples was 10 cm. The
biotinylated proteins were precipitated by streptavidin
sepharose (GE healthcare) in 1% SDS containing
homogenization buffer. For SCAM, all methanethiosul-
fonate reagents (Toronto Research Chemicals) were dis-
solved in dimethyl sulfoxide at 200 mM prior to use or
stored at 80 degree until use. The methods for SCAM
and competition experiments using biotinylaminoethyl
methanethiosulfonate have been described in detail be-
fore [10,11]. Briefly, stable DKO cells expressing cysteine
mutant PS1 were grown on two 15-cm dishes per single
analysis. Cells were scraped in PBS and resuspended in
2 ml of SCAM homogenization buffer (10 mM HEPES
(pH 7.4), 150 mM NaCl, 10% glycerol, Complete prote-
ase inhibitor cocktail (Roche Biochemicals)). Cells were
disrupted by a Polytron homogenizer (Hitachi), and nu-
clei and large cell debris were pelleted by centrifugation
at 1,500 × g for 10 min. The postnuclear supernatants
were centrifuged, and the resultant microsomal pellets
were resuspended in 0.2 ml of PBS in a syringe, and
0.1 mM biotinylaminoethyl methanethiosulfonate was
added to this fraction. After 30 min incubation at 4 de-
gree, microsomes were centrifuged twice to wash out.
The resultant pellets resuspended in 1% SDS/PBS were
incubated with the streptavidin sepharose overnight and
analyzed as in the intact cell biotinylation experiment. In
PAL or SCAM experiments, we loaded 1.5 and 20% of
samples as “input” and “bound”, respectively, in all im-
munoblot analyses.
Protein purification and binding assay
GST-fusion recombinant proteins were expressed in E.
Coli (BL21 DE3) (Novagen) and purified by two step
procedures using glutathione sepharose and mono Q
columns (GE Healthcare) as manufacturer’s instruction.
All recombinant proteins were finally diluted with re-
combinant protein preparation buffer (10 mM HEPES
(pH 7.4), 150 mM NaCl, 0.25% CHAPSO). C99-FLAG
was purified from Sf9 cells infected with recombinant
baculovirus encoding C99-FLAG and diluted at 1 μg/ml
in recombinant protein preparation buffer. To perform
binding assay, 0.5 μg of GST-fusion recombinant
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Aβ45, Aβ46, Aβ48 and Aβ49) or 10 (for Aβ40 and
Aβ42) nM of synthetic Aβ in 1 ml of recombinant pro-
tein preparation buffer, and incubated at 4 degree over-
night. After addition of glutathione sepharose, samples
were then washed with the buffer and precipitates were
eluted by boiling in sample buffer. For binding assay
using native PS1 protein, PS1 or P88L mutant PS1 was
expressed in DKO cells and solubilized in 10 mM
HEPES buffer containing 1% CHAPSO. After addition of
2 ng of Aβ48 peptide, the solubilized fraction was incu-
bated with anti-PS1 antibody G1Nr5 at 4 degree over-
night. PS1-Aβ48 complex was then immunoprecipitated
using Protein G sepharose 4 Fast Flow (GE Healthcare).
Subsequently eluates (i.e., proteins bound to GST-fusion
recombinant proteins or native PS1 proteins) were ana-
lyzed by immunoblotting. We loaded 0.75 and 20% of
samples as “input” and “bound”, respectively, in immu-
noblot of all pull down assay unless the amount of
loaded proteins was otherwise indicated.
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